Wind-dispelling stagnation-eliminating traditional Chinese medicine composition and application thereof

Abstract

The invention discloses a wind-dispelling stagnation-eliminating traditional Chinese medicine composition which is formed by compatibility of whole scorpion, centipede, radix astragali and black beancoat. The invention also discloses an application of the composition in preparation of drugs for treating rheumatoid arthritis bone erosion and rheumatoid arthritis. The wind-dispelling stagnation-eliminating traditional Chinese medicine composition is found out to inhibit the expression of IL-6 and RANKL in various cells of CIA mice joint parts, increase the expression of osteoprotegerin OPG, reduce the number of osteoclasts, increase bone density, alleviate bone erosion in CIA mice, and effectively alleviate CIA mice joint bone swelling and reduce injury of synovium of joint, and has pharmaceutical application prospect for related diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to a Soufeng Sanjie traditional Chinese medicine composition and its pharmaceutical application. Background technique [0002] Rheumatoid arthritis (RA) is known as "undead cancer" (Luo Anming et al. On the category of cancer belonging to "blocking phlegm" in traditional Chinese medicine. Chinese Journal of Basic Medicine of Traditional Chinese Medicine 2015,21(01):14-15 ), is a systemic autoimmune disease with erosive polyarthritis as the main manifestation. RA manifests as symmetrical arthritis in the early stage, and joint stiffness and deformity in the late stage. It is a common disease with high disability rate and great harm. difficult disease. It occurs in 0.5-1% of adults worldwide, and the incidence rate is higher in women than in men (Chung IM, et al. Rheumatoid Arthritis: The Stride from Research to Clinical Practice. International journal of molecular sciences, 2016; 1...

AI Technical Summary

Problems solved by technology

In the inflammatory state of RA, the release of various inflammatory factors such as TNF-a, IL-6, and IL-17 increases, which promotes the differentiation of osteoclasts, enhances the activity of osteoclasts, and limits the activity of osteoblasts, resulting in Bone metabolism disorder, leading to bone erosion (1.Abdel Meguid MH, etal.Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage.Rheumatol Int.2013Mar;33(3):697-703.2.Luo G, et al. TNF-a and RANKL promote osteoclastogenesis by upregulating RANK via the NF kappaB pathway. Molecular medicine reports 2018; 17:6605-6611.3. Ganesan R, et al. Interleukin 17 regulates SHP-2 and IL-17RA / STAT-3 dependent Cyr61 ,IL-23 and GM-CSF expression and RANKL mediatedosteoclastogenesis by fibroblast-like synoviocytes in rheumatoidarthritis. Molecular immunology 2017; 91:134-144) In summary, bone erosion is the bottleneck of current RA treatment, and overdifferentiation of osteoclasts is the An important cause of bone erosion in RA. RANKL / NF-κB / NFATc1 is a key signaling pathway mediating osteoclast differentiation. A variety of pro-inflammatory cytokines promote osteoclast differentiation. Therefore, bone erosion in RA is caused by multiple pathways. , multi-mechanism, single-target drug treatment, it is difficult to achieve better results

[0004] At present, anti-rheumatoid drugs (DMARDs) are mainly used to relieve joint swelling and inflammation in patients, but have no significant effect on improving bone erosion.

Antibody drugs that specifically target RANKL, although they can slow down the progression of the disease, have no definitive effect on bone erosion

Images